TY - JOUR
T1 - 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis
AU - for the DCVAS Study Group
AU - Robson, Joanna C.
AU - Grayson, Peter C.
AU - Ponte, Cristina
AU - Suppiah, Ravi
AU - Craven, Anthea
AU - Judge, Andrew
AU - Khalid, Sara
AU - Hutchings, Andrew
AU - Watts, Richard A.
AU - Merkel, Peter A.
AU - Luqmani, Raashid A.
AU - Gatenby, Paul
AU - Hill, Catherine
AU - Ranganathan, Dwarakanathan
AU - Kronbichler, Andreas
AU - Blockmans, Daniel
AU - Barra, Lillian
AU - Carette, Simon
AU - Pagnoux, Christian
AU - Dhindsa, Navjot
AU - Fifi-Mah, Aurore
AU - Khalidi, Nader
AU - Liang, Patrick
AU - Milman, Nataliya
AU - Pineau, Christian
AU - Tian, Xinping
AU - Wang, Guochun
AU - Wang, Tian
AU - Zhao, Ming hui
AU - Tesar, Vladimir
AU - Baslund, Bo
AU - Hammam, Nevin
AU - Shahin, Amira
AU - Pirila, Laura
AU - Putaala, Jukka
AU - Hellmich, Bernhard
AU - Henes, Jörg
AU - Lamprecht, Peter
AU - Neumann, Thomas
AU - Schmidt, Wolfgang
AU - Sunderkoetter, Cord
AU - Szekanecz, Zoltan
AU - Danda, Debashish
AU - Das, Siddharth
AU - Gupta, Rajiva
AU - Rajasekhar, Liza
AU - Sharma, Aman
AU - Wagh, Shrikant
AU - Clarkson, Michael
AU - Molloy, Eamonn
N1 - Publisher Copyright:
© 2022 American College of Rheumatology.
PY - 2022/3
Y1 - 2022/3
N2 - Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting, or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (+5); pulmonary nodules, mass, or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci-immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (−1); and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% confidence interval [95% CI] 87–96%) and the specificity was 94% (95% CI 89–97%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research.
AB - Objective: To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in 5 phases: 1) identification of candidate criteria items using consensus methodology, 2) prospective collection of candidate items present at the time of diagnosis, 3) data-driven reduction of the number of candidate items, 4) expert panel review of cases to define the reference diagnosis, and 5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators. Results: The development set for GPA consisted of 578 cases of GPA and 652 comparators. The validation set consisted of an additional 146 cases of GPA and 161 comparators. From 91 candidate items, regression analysis identified 26 items for GPA, 10 of which were retained. The final criteria and their weights were as follows: bloody nasal discharge, nasal crusting, or sino-nasal congestion (+3); cartilaginous involvement (+2); conductive or sensorineural hearing loss (+1); cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti–proteinase 3 ANCA positivity (+5); pulmonary nodules, mass, or cavitation on chest imaging (+2); granuloma or giant cells on biopsy (+2); inflammation or consolidation of the nasal/paranasal sinuses on imaging (+1); pauci-immune glomerulonephritis (+1); perinuclear ANCA or antimyeloperoxidase ANCA positivity (−1); and eosinophil count ≥1 × 109/liter (−4). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having GPA if the cumulative score was ≥5 points. When these criteria were tested in the validation data set, the sensitivity was 93% (95% confidence interval [95% CI] 87–96%) and the specificity was 94% (95% CI 89–97%). Conclusion: The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for GPA demonstrate strong performance characteristics and are validated for use in research.
UR - http://www.scopus.com/inward/record.url?scp=85125053824&partnerID=8YFLogxK
U2 - 10.1002/art.41986
DO - 10.1002/art.41986
M3 - Journal articles
C2 - 35106964
AN - SCOPUS:85125053824
SN - 2326-5191
VL - 74
SP - 393
EP - 399
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
IS - 3
ER -